The annual San Antonio Breast Cancer meeting in 2023 highlighted advancements in metastatic breast cancer treatment, which affects 40,000 women and 4,000 men in the US annually. CDK4/6 inhibitors have improved progression-free survival, but resistance remains a challenge. New therapies like Olaparib, capivasertib, and everolimus are showing promise for resistant patients. Precision oncology screening is being used to tailor treatments, with therapies like Enhertu reducing toxicity. Clinical trials are exploring new CDK2 inhibitors and combination therapies. The focus on drug-resistant breast cancer may lead to treatments applicable to other tumor types, emphasizing the importance of personalized care and expanding treatment options for patients.
Source link
The Future of Innovation Metastatic Breast Cancer: 2024 Outlook
